Avivo BiOptics: Illuminating Risk
Katie Couric joined Kimmel for his first colonoscopy. Jimmy Kimmel Live/YouTube
ABO's InPoint™ system provides a minimally invasive colorectal cancer diagnosis, that requires no bowel preparation or sedation.
Pioneering Colon Cancer Screening Through Innovative Optical Technologies
Avivo BioOptics (American BioOptics at the time) is a medical device company developing innovative diagnostic tools to identify patients at a high risk for colorectal cancer based upon a suite of pioneering optical technologies, including four-dimensional elastic light-scattering fingerprinting. Their innovative InPoint™ System illuminates the risk of Colorectal cancer immediately and accurately to identify high-risk patients that need further evaluation.
The InPoint™ system assesses a patient’s risk of developing cancer. The InPoint™ system’s Low-coherence Enhanced Backscattering (LEBS) technology is an optical platform that examines and analyses nanoscopic structural tissue changes. The technology is based on the concept of field carcinogenesis – during the initial stages of cancer, tissue changes spread throughout the organ due to common environmental disturbances and genetic composition. These changes are identified by the reflection of light from the tissue. LEBS measures changes at a specific area (rectum) that are indicative of the entire organ examined (colon).
Over the course of summer 2018, I worked on a number of projects with Avivo BioOptics from sourcing parts for the Beta version of the diagnostic device, to building the companies web-presence. It was an environment that allowed me to hone my critical thinking and interpersonal skills, whilst introducing me to new areas, such as revenue forecasts, product profiles, and fundraising.
Skills learned
• Utilised CSS, HTML, and Javascript to build the companies website
• Worked with in-house engineers to develop the quality assessment system
• Worked with a contract research organisation for preclinical trials of the InPoint™ System
• Facilitated in the negotiations and procurement with manufacturers for novel parts of the Beta version of the diagnostic device
• Developed an investor portfolio and investor pitch deck for series A round of fundraising.
Description
Avivo BioOptics
Avivo BioOptics’ (ABO) is revolutionising cancer screening process with the introduction of the InPoint™ System. The first point-of-care, personalised cancer risk assessment to provide immediate and accurate results to identify high-risk patients needing further evaluation. The first application of use is for Colorectal cancer (CRC).